Affordable Access

Inhibitors of Catechol-O-Methyltransferase.

Authors
Type
Published Article
Journal
CNS & neurological disorders drug targets
Publication Date
Volume
11
Issue
3
Pages
324–332
Identifiers
PMID: 22483290
Source
Medline

Abstract

Since the identification of Catechol-O-Methyltransferase (COMT) by Axelrod in 1957, many inhibitors of this enzyme have been reported. While COMT inhibition may be beneficial in a number of disease states, most of the effort over the years has been directed at boosting L-DOPA concentrations as adjunct treatment for Parkinson's disease. This review summarizes the major classes of COMT inhibitors, from early catechol and pyrogallol variants to bisubstrate inhibitors. The nitrocatechol substructure has proven to be a particularly productive scaffold, resulting in two marketed drugs and several improved drug candidates working their way through clinical trials.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F